Topic resource collection
Approved comparison material connected to this topic.
3 resourcesRead both sides
GHK-Cu and BPC-157 both target ECM remodelling in liver fibrosis but through mechanistically distinct pathways that are potentially additive. GHK-Cu primarily addresses the oxidative stress-HSC activation axis (Nrf2-ROS suppressi…
Thymalin T-cell receptor modulation, reduces IL-6/TNF-alpha hepatic inflammation 5–10mg, 2–3x weekly, 4–8 week cycles Rodent NAFLD models show 41% reduction in inflammatory infiltrates (Molecular Medicine Reports, 2023) Best-supp…
BPC-157 VEGF modulation, NF- B inhibition, stellate cell suppression 200–500 mcg SQ daily (human equivalent from animal models) Preclinical only. No Phase III human trials Strongest evidence for fibrosis reduction in CCl4 and alc…